AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry

VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study(1) Data support findings from previous HCV Phase 3 clinical trials with VIEKIRAX a... BiopharmaceuticalsAbbVie, hepatitis C, VIEKIRAX, EXVIERA

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2041053

Source: HSMN NewsFeed - April 15, 2016 Category: Pharmaceuticals Source Type: news